N-Acetyl Cysteine and Improved Event-Free Survival

• Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation.

  • 2023-03-23
  • RCT · n = 78
  • American journal of hematology 98(6)
  • • Yaqiong Tang
    • Ziyan Zhang
    • Silu Liu
    • Yifang Yao
    • Tingting Pan
    • Jiaqian Qi
    • Huizhu Kang
    • Yuejun Liu
    • Chengsen Cai
    • Meng Zhou
    • Xuefeng He
    • Xiaohui Hu
    • Xiao Ma
    • Depei Wu
    • Yue Han

  • PubMed: 36880836
  • DOI: 10.1002/ajh.26903

  5 Insights on

  • Improved Event-Free Survival

  • High evidence
  • Clinical

  EFS at 3 years was 79.2% (±4.9%) in Arm A and 60.0% (±5.9%) in Arm B (p = .007).

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes

  Dose

  Not explicitly stated in abstract